GLP-1研究驱动着主要的糖尿病和减重药物,是2025年诺贝尔奖的投机领先。 GLP-1 research, driving major diabetes and weight-loss drugs, is leading Nobel Prize speculation for 2025.

研究GLP-1, 即调节胃口的荷尔蒙, 正在引发2025年诺贝尔生理学或医学奖的投机, 原因是体重损失和糖尿病药物(如Ozempic和Wegovy)的全球性影响。 Research into GLP-1, a hormone regulating appetite, is leading speculation for the 2025 Nobel Prize in Physiology or Medicine due to the global impact of weight-loss and diabetes drugs like Ozempic and Wegovy. 包括Jens Juul Holst、Joel Habener、Daniel Drucker和Svetlana Mojsov在内的科学家在1980年代首次确认的GLP-1基本工作被引述。 Scientists including Jens Juul Holst, Joel Habener, Daniel Drucker, and Svetlana Mojsov are cited for their foundational work on GLP-1, first identified in the 1980s. 对ghrelin和leptin的平行研究,包括日本和美国科学家的工作,也为该领域的突出地位作出了贡献。 Parallel research on ghrelin and leptin, including work by Japanese and U.S. scientists, also contributes to the field’s prominence. 其他潜在的诺贝尔奖竞赛者包括原生免疫和白血病干细胞生物学方面的研究人员。 Other potential Nobel contenders include researchers in innate immunity and leukemia stem cell biology. 10月6日至13日将宣布诺贝尔奖,每人获得120万美元的奖项。 The Nobel Prizes will be announced from October 6 to 13, each carrying a $1.2 million award. 美国科学资金的削减已经终止了数千笔NIH赠款,引起了人们对美国长期研究领导能力的疑问。 Concerns persist over U.S. science funding cuts, which have terminated thousands of NIH grants, raising questions about America’s long-term research leadership.